The Impact of Opioid Treatment on Regional Gastrointestinal Transit

Overview

Journal J Neurogastroenterol Motil

Date 2016 Jan 27

PMID 26811503

Citations 22

Authors

Jakob L Poulsen

Matias Nilsson

Christina Brock

Thomas H Sandberg

Klaus Krogh

Asbjorn M Drewes

Affiliations

Soon will be listed here.

Abstract

Background/aims: To employ an experimental model of opioid-induced bowel dysfunction in healthy human volunteers, and evaluate the impact ofopioid treatment compared to placebo on gastrointestinal (GI) symptoms and motility assessed by questionnaires and regional GItransit times using the 3-dimensional (3D)-Transit system.

Methods: Twenty-five healthy males were randomly assigned to oxycodone or placebo for 5 days in a double blind, crossover design. AdverseGI effects were measured with the bowel function index, gastrointestinal symptom rating scale, patient assessment of constipationsymptom questionnaire, and Bristol stool form scale. Regional GI transit times were determined using the 3D-Transit system, and segmental transit times in the colon were determined using a custom Matlab(®) graphical user interface.

Results: GI symptom scores increased significantly across all applied GI questionnaires during opioid treatment. Oxycodone increased median total GI transit time from 22.2 to 43.9 hours (P < 0.001), segmental transit times in the cecum and ascending colon from 5.7 to 9.9 hours (P = 0.012), rectosigmoid colon transit from 2.7 to 9.0 hours (P = 0.044), and colorectal transit time from 18.6 to 38.6 hours (P= 0.001). No associations between questionnaire scores and segmental transit times were detected.

Conclusions: Self-assessed GI adverse effects and increased GI transit times in different segments were induced during oxycodone treatment. This detailed information about segmental changes in motility has great potential for future interventional head-to-head trials of different laxative regimes for prevention and treatment of constipation.

Citing Articles

Understanding the impact of the gut microbiome on opioid use disorder: Pathways, mechanisms, and treatment insights.

Kazemian N, Pakpour S Microb Biotechnol. 2024; 17(10):e70030.

PMID: 39388360 PMC: 11466222. DOI: 10.1111/1751-7915.70030.

Review article: Current status and future directions of ingestible electronic devices in gastroenterology.

Thwaites P, Yao C, Halmos E, Muir J, Burgell R, Berean K Aliment Pharmacol Ther. 2024; 59(4):459-474.

PMID: 38168738 PMC: 10952964. DOI: 10.1111/apt.17844.

Opioid trail: Tracking contributions to opioid use disorder from host genetics to the gut microbiome.

Duffy E, Bachtell R, Ehringer M Neurosci Biobehav Rev. 2023; 156:105487.

PMID: 38040073 PMC: 10836641. DOI: 10.1016/j.neubiorev.2023.105487.

Bowel dysfunctions after acquired brain injury: a scoping review.

Zandalasini M, Pelizzari L, Ciardi G, Giraudo D, Guasconi M, Paravati S Front Hum Neurosci. 2023; 17:1146054.

PMID: 37900728 PMC: 10602674. DOI: 10.3389/fnhum.2023.1146054.

Iatrogenic Side Effects of Pain Therapies.

Gharibo C, Drewes A, Breve F, Rekatsina M, Narvaez Tamayo M, Varrassi G Cureus. 2023; 15(9):e44583.

PMID: 37790027 PMC: 10545448. DOI: 10.7759/cureus.44583.

References

Gaertner J, Siemens W, Camilleri M, Davies A, Drossman D, Webster L . Definitions and outcome measures of clinical trials regarding opioid-induced constipation: a systematic review. J Clin Gastroenterol. 2014; 49(1):9-16. DOI: 10.1097/MCG.0000000000000246. View

Jeong I, Camilleri M, Shin A, Iturrino J, Boldingh A, Busciglio I . A randomised, placebo-controlled trial comparing the effects of tapentadol and oxycodone on gastrointestinal and colonic transit in healthy humans. Aliment Pharmacol Ther. 2012; 35(9):1088-96. DOI: 10.1111/j.1365-2036.2012.05040.x. View

Casati A, Sedefov R, Pfeiffer-Gerschel T . Misuse of medicines in the European Union: a systematic review of the literature. Eur Addict Res. 2012; 18(5):228-45. DOI: 10.1159/000337028. View

Hiroz P, Schlageter V, Givel J, Kucera P . Colonic movements in healthy subjects as monitored by a Magnet Tracking System. Neurogastroenterol Motil. 2009; 21(8):838-e57. DOI: 10.1111/j.1365-2982.2009.01298.x. View

Staahl C, Christrup L, Andersen S, Arendt-Nielsen L, Drewes A . A comparative study of oxycodone and morphine in a multi-modal, tissue-differentiated experimental pain model. Pain. 2006; 123(1-2):28-36. DOI: 10.1016/j.pain.2006.02.006. View

FRANK L, Kleinman L, Farup C, Taylor L, Miner Jr P . Psychometric validation of a constipation symptom assessment questionnaire. Scand J Gastroenterol. 1999; 34(9):870-7. DOI: 10.1080/003655299750025327. View

Moore J, Barlow D, Jewell D, Kennedy S . Do gastrointestinal symptoms vary with the menstrual cycle?. Br J Obstet Gynaecol. 1999; 105(12):1322-5. DOI: 10.1111/j.1471-0528.1998.tb10014.x. View

Brock C, Olesen S, Olesen A, Frokjaer J, Andresen T, Drewes A . Opioid-induced bowel dysfunction: pathophysiology and management. Drugs. 2012; 72(14):1847-65. DOI: 10.2165/11634970-000000000-00000. View

Pappagallo M . Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg. 2002; 182(5A Suppl):11S-18S. DOI: 10.1016/s0002-9610(01)00782-6. View

10.

Sandler R, Jordan M, Shelton B . Demographic and dietary determinants of constipation in the US population. Am J Public Health. 1990; 80(2):185-9. PMC: 1404600. DOI: 10.2105/ajph.80.2.185. View

11.

Musial F, Enck P, Kalveram K, Erckenbrecht J . The effect of loperamide on anorectal function in normal healthy men. J Clin Gastroenterol. 1992; 15(4):321-4. DOI: 10.1097/00004836-199212000-00011. View

12.

Yuan C, Foss J, Osinski J, Toledano A, Roizen M, Moss J . The safety and efficacy of oral methylnaltrexone in preventing morphine-induced delay in oral-cecal transit time. Clin Pharmacol Ther. 1997; 61(4):467-75. DOI: 10.1016/S0009-9236(97)90197-1. View

13.

Heitkemper M, Jarrett M . Pattern of gastrointestinal and somatic symptoms across the menstrual cycle. Gastroenterology. 1992; 102(2):505-13. DOI: 10.1016/0016-5085(92)90097-i. View

14.

Kang M, Maguma H, Smith T, Ross G, Dewey W, Akbarali H . The role of β-arrestin2 in the mechanism of morphine tolerance in the mouse and guinea pig gastrointestinal tract. J Pharmacol Exp Ther. 2011; 340(3):567-76. PMC: 3286318. DOI: 10.1124/jpet.111.186320. View

15.

Saad R, Rao S, Koch K, Kuo B, Parkman H, McCallum R . Do stool form and frequency correlate with whole-gut and colonic transit? Results from a multicenter study in constipated individuals and healthy controls. Am J Gastroenterol. 2009; 105(2):403-11. DOI: 10.1038/ajg.2009.612. View

16.

Olesen A, Drewes A . Validated tools for evaluating opioid-induced bowel dysfunction. Adv Ther. 2011; 28(4):279-94. DOI: 10.1007/s12325-011-0006-4. View

17.

Johanson J, Kralstein J . Chronic constipation: a survey of the patient perspective. Aliment Pharmacol Ther. 2007; 25(5):599-608. DOI: 10.1111/j.1365-2036.2006.03238.x. View

18.

Hedsund C, Moeller Joensson I, Gregersen T, Fynne L, Schlageter V, Krogh K . Magnet tracking allows assessment of regional gastrointestinal transit times in children. Clin Exp Gastroenterol. 2014; 6:201-8. PMC: 3875367. DOI: 10.2147/CEG.S51402. View

19.

Wood J, Galligan J . Function of opioids in the enteric nervous system. Neurogastroenterol Motil. 2004; 16 Suppl 2:17-28. DOI: 10.1111/j.1743-3150.2004.00554.x. View

20.

Drewes A, Gregersen H, Arendt-Nielsen L . Experimental pain in gastroenterology: a reappraisal of human studies. Scand J Gastroenterol. 2003; 38(11):1115-30. DOI: 10.1080/00365520310004399. View